Janssen (J&J) BCG-unresponsive: 84 treatments! Too early for us in the jv process, but you could imagine it could be our own story soon ...
And imagine if they would compare key elements (# of doses, toxicity, efficacy, etc ...) of their BCG-Unresponsive Ph. 2 trial with ours!!!
Consider this J&J's Janssen Ph. 2 NMIBC BCG-Unresponsive trial:
four (4) consecutive 21 day cycles of TAR-200 of chemo
there are some lackluster preliminary results fromJanssen's (Pharma division of J&J) Ph 2 SunRISe-1 study, which includes their investigational anti-PD-1 drug, cetrelimab. In their April 30, 2023 announcement, systemic cetrelimab monotherapy demonstrated only a38.1% CR to date. The above study is also investigating a novel type of continuous intravesical therapy using chemo (TAR-200 monotherapy), which has demonstrated promising CR results to date. However, the treatment involves four consecutive 21 day cycles of TAR-200 (over "84" days of treatment). Consequently, there have been significant adverse events (AEs). Initial findings demonstrated that 30.4% of treated patients had experienced AEs of "grade 3 or higher". A grade 3 AE is severe & generally requires some type of medical intervention, which can include hospitalization. A grade 4 AE is life-threatening & requires intensive or emergent care.
Now. consider this May 15 article excerpts:
Identifying 'gems' before others do: J&J exec gives insider's look at dealmaking spree
https://www.fiercebiotech.com/biotech/identifying-gems-others-do-jj-gives-insiders-look-its-deal-making-spree
When it comes to seeking out eye-catching data like these, Shah and his team try to cast a wide net.
“Sometimes things catch our eye in certain meetings, in certain settings, or maybe a connection at a conference like J.P. Morgan,” he explains.
“But truly, foremost, what catches our eye is incredible science. We're not chasing deals or therapies because others are chasing them, we're actually chasing truly transformational science.”
“We pride ourselves in having great insights,” Shah continues. “I'm surrounded by an incredible group of colleagues who have the fortitude to be able to look ahead to decipher data to identify key gems that are out there before others do.”
“We established a very strong connectivity with xxxxxxxxx and the management team there a number of months ago,” he said. “We did a lot of our own evaluation, starting in the science, evaluating the molecule and then ultimately assessing it holistically to come forward with a deal.”
...
“This is ultimately a marriage that comes to fruition after a number of discussions in which we're looking to create mutual success,” he says. “Obviously you want to have a partnership grounded in trust, transparency—you want to feel good about who you're partnering with.”
“So that's really what drove our interest,” he adds. “And ultimately, we were able to drive the right deal structure that not only met our needs, but ultimately met the needs of Yumanity’s shareholders.”
...